

Post-transplantation Burkitt lymphoma: a retrospective study of 55 patients

Pierre Walczak,¹ Sylvain Choquet,¹ Jacques Dantal,² David Boutboul,³ Felipe Suarez,⁴ Marine Baron,¹ Véronique Morel,¹ Thomas Cluzeau,⁵ Mohamed Touati,⁶ Michelle Elias,⁷ Emmanuel Bachy,⁸ Emmanuelle Nicolas-Virelizier,⁹ Roch Houot,¹⁰ Geoffroy Venton,¹¹ Caroline Jacquet,¹² Marie-Pierre Moles-Moreau,¹³ Fabrice Jardin,¹⁴ Eric Durot,¹⁵ Nouredine Balegrone,¹ Laure Ecotière,¹⁶ Romain Guièze,¹⁷ Nassim Kamar,¹⁸ Loïc Ysebaert,¹⁹ Lionel Couzi,²⁰ Hugo Gonzalez,²¹ Louise Roulin,²² Kevin Ou,²³ Sophie Caillard,²⁴ Heiner Zimmermann,^{25,26} Ralf Ulrich Trappe,^{26,27} and Damien Roos-Weil¹ for the K-VIROGREF study group


¹Sorbonne Université, Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, APHP, Paris, France; ²Institut de Transplantation Urologie Néphrologie (ITUN), Service de Néphrologie et Immunologie clinique, CHU Nantes, Nantes, France; ³Service d'Immunologie Clinique, Hôpital Saint-Louis, APHP, Paris, France; ⁴Service d'Hématologie Clinique, Hôpital Necker, APHP, Paris, France; ⁵Service d'Hématologie Clinique, CHU de Nice, Nice, France; ⁶Service d'Hématologie Clinique, CHU Limoges, Limoges, France; ⁷Service de Néphrologie, Hôpital Saint-Louis, APHP, Paris, France; ⁸Service d'Hématologie Clinique, Hospices Civils de Lyon, Pierre-Bénite, France; ⁹Service d'Hématologie, Centre Léon Bérard, Lyon, France; ¹⁰Service d'Hématologie, CHU Rennes, Université de Rennes, INSERM U1236, Rennes, France; ¹¹Service d'Hématologie et Thérapie Cellulaire, Hôpital universitaire de la Conception, Marseille, France; ¹²Service d'Hématologie, CHU de Nancy, Vandoeuvre les Nancy, France; ¹³Service d'Hématologie, CHU d'Angers, Angers, France; ¹⁴Service d'Hématologie, Centre Henri Becquerel, Rouen, France; ¹⁵CHU Reims, Hématologie Clinique, Reims, France; ¹⁶Service de Néphrologie, Hémodialyse et Transplantation Renale, Centre Hospitalier Universitaire de Poitiers, Poitiers, France; ¹⁷Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Clermont-Ferrand, Clermont-Ferrand, France; ¹⁸Service de Néphrologie et Transplantation d'Organes, CHU Rangueil, Toulouse, France; ¹⁹Service d'Hématologie, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France; ²⁰Service de Néphrologie, Transplantation, Dialyse et Aphérèses, CHU Bordeaux, France; ²¹Service d'Hématologie, Centre Hospitalier René-Dubos, Pontoise, France; ²²Service Unité Hémopathies Lymphoïdes, Groupe Hospitalo-universitaire Chenevier Mondor, APHP Créteil, France; ²³Service de Néphrologie et Transplantation Rénale, Hôpital Foch, Suresnes, France; ²⁴Service de Néphrologie et Transplantation Rénale, CHU de Strasbourg, Strasbourg, France; ²⁵Department of Internal Medicine-Oncology, Carl v. Ossietzky University of Oldenburg, Pius-Hospital, Oldenburg, Germany; ²⁶Department of Hematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus Bremen, Bremen, Germany and ²⁷Department of Internal Medicine II: Hematology and Oncology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany

Correspondence:

D. ROOS-WEIL - damien.roosweil@aphp.fr.

<https://doi.org/10.3324/haematol.2022.282297>

Supplementary Figure S1. Flow-chart of different frontline therapies.



Abbreviations: BL-PTLD: Burkitt lymphoma post-transplant lymphoproliferative disorder; CHOP: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; COPADEM: Vincristine, Methotrexate, Cyclophosphamide, Doxorubicin, Prednisone; EPOCH: Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone; HD MTX: High Dose Methotrexate; HyperCVAD: Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone; R: Rituximab; WBRT: Whole Brain Radiation Therapy

Supplementary Table S1. Patient characteristics according to first-line therapeutic strategy

Patient characteristics	Sequential treatment	Frontline CIT/CT	P value
Mean ECOG score (standard deviation)	0.6 (0.91)	1.61 (0.86)	0.01
Median age at time of diagnosis [IQR]	36.5 [30.4-49.2]	40.4 [29.4-54.1]	0.41
Extranodal disease	11 (78.6)	36 (92.3)	0.18
Bone	3 (21.4)	9 (23.1)	1.00
Digestive tract	8 (57.1)	19 (48.7)	0.77
Liver	3 (21.4)	11 (28.2)	1.00
Lung	0 (0)	3 (7.7)	0.55
Kidney	0 (0)	2 (5.1)	1.00
CNS involvement	0 (0)	7 (18.0)	0.2
Pleural/peritoneal	0 (0)	4 (10.3)	0.56
Graft	0 (0)	4 (10.3)	0.56
Bone marrow	5 (31.3)	18 (46.2)	0.55

Abbreviations: CIT, chemoimmunotherapy; CT, chemotherapy; CNS, central nervous system; IQR, interquartile.

Supplementary Table S2. Causes of death

Cause of death	N (%)
Progressive disease	11 (37.9)
Treatment toxicity*	7 (24.1)
During frontline R-EPOCH	1 (3.4)
During frontline R-COPADEM	2 (6.9)
During frontline R-CHOP	2 (6.9)
During salvage R-Cytarabine	1 (3.4)
During salvage R-Cytarabine-Thiotepa	1 (3.4)
Unrelated cancer	3 (10.3%)
Bladder cancer	1 (3.4)
Myelodysplastic syndrome	1 (3.4)
Different PTLD	1 (3.4)
Cardiovascular disease	4 (13.8)
Acute renal injury	1 (3.4)
Pulmonary graft dysfunction**	1 (3.4)
Unknown	2 (6.9)

*Due to sepsis, except for the death during R-EPOCH treatment (cerebral hemorrhage)

**Due to reduction of immunosuppression in the BL-PTLD context